Sallstig, Peter,Schmidt, Werner,Gekkieva, Margarita,Warburton, James,Weichselberger, Andreas
申请号：
AU2020220210
公开号：
AU2020220210A1
申请日:
2020.08.21
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020220210A120201001.pdf#####C: Interwovn NRPortbl DCC DAR 18170646 .docx-I/ 122018 Abstract A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.WO 2016/073918 PCT/US2015/059575 FIG.1 Week 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 RT11258 RT11258 q8 R'l 258 Disease activity assessment =RTH258 injection q12 = treatment every 12 weeks qS = treatment every 8 weeks switch to qS if any disease activity assessment criterion met 1/1
